25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
In DealLawyers.com, John Jenkins calls attention to U.S. District Court Judge Timothy S. Hillman's d...
Read More >
In White Constructions Pty Ltd v PBS Holdings Pty Ltd [2019] NSWSC 1166 the Supreme Court of New Sou...
Read More >
Welcome to a special five-part podcast series from the Compliance Podcast Network. In this series I ...
Read More >
The final installment of this blog series discussing changes made by the Setting Every Community Up ...
Read More >
In 2018, Governor Cuomo signed a State Budget bill that included various provisions addressing sexua...
Read More >
Oregon’s Legislature just enacted the most significant legislation for Oregon employers in years. T...
Read More >